Abstract
The pharmacokinetics of moxifloxacin was studied in 17 mechanically ventilated patients with pneumonia. Patients were given 400 mg of moxifloxacin intravenously. Blood samples and bronchial secretions were taken on days 1 and 4. A dose of 400 mg of moxifloxacin allows one to achieve efficient concentrations in bronchial secretions and plasma.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Anti-Infective Agents / administration & dosage
-
Anti-Infective Agents / pharmacokinetics*
-
Area Under Curve
-
Aza Compounds / administration & dosage
-
Aza Compounds / pharmacokinetics*
-
Bronchi / metabolism*
-
Female
-
Fluoroquinolones
-
Half-Life
-
Humans
-
Injections, Intravenous
-
Male
-
Moxifloxacin
-
Pneumonia / metabolism*
-
Pneumonia / therapy
-
Quinolines / administration & dosage
-
Quinolines / pharmacokinetics*
-
Respiration, Artificial*
Substances
-
Anti-Infective Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
Moxifloxacin